News & Updates

The use of fremanezumab is safe and effective for the prevention of episodic migraine (EM) in children and adolescents as young as 6 years old, according to a study presented at AAN 2025.

Treatment with tolebrutinib results in a clear reduction in disability accumulation in patients with relapsing multiple sclerosis (MS) compared with teriflunomide despite no difference in relapses, according to the findings of the GEMINI 1 and 2 trials presented at AAN 2025.

Catheter ablation appears to be an effective procedure for patients with ventricular arrhythmias in the early phase following acute coronary syndrome (ACS), as shown by a study presented at EHRA 2025.

In the treatment of early Alzheimer’s disease (AD), lecanemab is as safe and efficacious in Asian patients as in the wider Clarity AD population, slowing cognitive decline and reducing amyloid levels in the brain with manageable risks.

Treatment with self-administered etripamil results in the termination of paroxysmal supraventricular tachycardia (PSVT) episodes among Chinese patients in an at-home setting, according to a study presented at EHRA 2025.